Friedberg & LeBaron (2026)
- Authors: Fred Friedberg, Tyler W. LeBaron
- Institutes: Stony Brook University, Stony Brook, United States, Southern Utah University, Cedar City, United States
- Publisher: Frontiers in Medicine
- Link: DOI
Summary
This review identifies molecular hydrogen as a promising, low-risk adjunctive therapy for ME/CFS by targeting core biological issues like oxidative stress and mitochondrial dysfunction. While the current clinical evidence is based on small pilot studies, the observed improvements in fatigue and physical function suggest it may offer a safe way to manage symptoms. Its potential applicability to Long COVID further highlights its relevance as a broad-spectrum intervention for post-viral conditions.
What was researched?
The review examined the therapeutic potential of molecular hydrogen 💊, primarily administered as hydrogen-rich water, for treating ME/CFS. Researchers evaluated its biological mechanisms and summarized findings from three early-stage clinical studies.
Why was it researched?
ME/CFS lacks FDA-approved treatments and is characterized by oxidative stress, chronic inflammation, and impaired energy metabolism. Molecular hydrogen was researched because its selective antioxidant and anti-inflammatory properties directly align with these known biological abnormalities.
How was it researched?
The authors conducted a narrative mini-review of mechanistic evidence and analyzed results from three developmental clinical trials involving patients with ME/CFS. They also looked at overlapping data from studies on Long COVID to assess the broader applicability of the treatment.
What has been found?
Preliminary evidence suggests that consuming moderate doses of hydrogen-rich water over extended periods can reduce fatigue and improve physical function. The treatment was found to be feasible with generally mild side effects, although the studies were limited by small sample sizes. Mechanistically, molecular hydrogen appears to support mitochondrial health and cellular homeostasis.
Discussion
The primary limitations of the current research include the small number of participants and a heavy reliance on self-reported outcomes rather than objective biomarkers. There is a clear need for more rigorous study designs to confirm these early positive signals.
Conclusion & Future Work
Molecular hydrogen represents a promising, low-burden therapy that warrants further investigation through larger, randomized controlled trials. Future studies should include remote biometric monitoring and biochemical assessments to better identify which patient subgroups respond best to the treatment.